益赛普对强直性脊柱炎患者关节活动性指标的影响

Effect of etanercept in patients with ankylosing spondylitis joint activity index

目的讨论益赛普对强直性脊柱炎患者关节活动指标的影响,为强直性脊柱炎患者临床治疗提供理论参考。方法选择2016年1月~2017年3月于本院风湿疼痛科进行治疗的强直性脊柱炎患者50例,随机分成两组,每组25例患者;对照组给予柳氮磺胺吡啶+甲氨蝶呤,观察组患者服用益赛普+甲氨蝶呤;观察并比较两组患者治疗后关节活动性指标的变化,根据患者关节临床症状改善情况对患者治疗临床疗效进行评估,并比较两组患者治疗后不良反应发生情况。结果治疗后,两组患者胸廓扩张度、脊柱侧弯、强直性脊柱炎病情活动指标(BASDAI)、血清C反应蛋白(CRP)、红细胞沉降率(ESR)、脊柱痛VAS评分以及晨僵时间均较治疗前改善,且观察组改善程度明显优于对照组,差异有统计学意义(P<0.05);观察组总有效率(96.0%)明显高于对照组(68.0%),不良反应发生率(16.0%)明显低于对照组(48.0%),差异均有统计学意义(P<0.05)。结论益赛普治疗强直性脊柱炎临床疗效显著,能明显改善患者关节疼痛等临床症状,改善患者关节功能,且安全性较高,值得临床推广使用。

Objective To discuss the effect of etanercept in patients with ankylosing spondylitis joint activity index, and provide a theoretical reference for the clinical treatment of patients with ankylosing spondylitis. Methods Selected 50 cases of ankylosing spondylitis patients treated with rheumatic pain in our hospital from January 2016 to March 2017, and randomly divided into two groups, 25 patients in each group; The control group was treated with sulfasalazine and methotrexate, the observation group patients taking etanercept and methotrexate; changes in joint activity in- dex were observed and compared between the two groups after treatment, the clinical efficacy of the patients was evaluated according to the improve- ment of the clinical symptoms of the patients, the occurrence of adverse reactions were compared between the two groups after treatment. Results After treatment, two groups of patients with thoracic expansion, scoliosis, BASDAI, CRP, ESR, spinal pain VAS score and morning stiffness time were better than those before treatment, and the observation group improved significantly better than the control group, the difference were statistical- ly significant （P〈0.05）; the total efficiency of the observation group （96.0%） significantly higher than the control group （68.0%）, the adverse reaction rate of the observation group （16.0%） was significantly lower than the control group （48.0%）, the difference were statistically significant （P〈 0.05）. Conclusion Etanercept treatment of ankylosing spondylitis patients can significantly improve the clinical symptoms of joint pain, improve joint function of patients,it has high security and is worthy of clinical application.